<?xml version='1.0' encoding='utf-8'?>
<document id="20523867"><sentence text="Reduced exposure of imatinib after coadministration with acetaminophen in mice."><entity charOffset="20-28" id="DDI-PubMed.20523867.s1.e0" text="imatinib" /><entity charOffset="57-70" id="DDI-PubMed.20523867.s1.e1" text="acetaminophen" /><pair ddi="false" e1="DDI-PubMed.20523867.s1.e0" e2="DDI-PubMed.20523867.s1.e0" /><pair ddi="false" e1="DDI-PubMed.20523867.s1.e0" e2="DDI-PubMed.20523867.s1.e1" /></sentence><sentence text="Imatinib is an efficacious drug against chronic myeloid leukemia (CML) and gastrointestinal stromal tumor (GIST) due to selective inhibition of c-KIT and BCR-ABL kinases"><entity charOffset="0-8" id="DDI-PubMed.20523867.s2.e0" text="Imatinib" /></sentence><sentence text=" It presents almost complete bioavailability, is eliminated via P450-mediated metabolism and is well tolerated" /><sentence text=" However, a few severe drug-drug interactions have been reported in cancer patients taking acetaminophen"><entity charOffset="91-104" id="DDI-PubMed.20523867.s4.e0" text="acetaminophen" /></sentence><sentence text="" /><sentence text="Male ICR mice were given 100 mg/kg single dose of imatinib orally or imatinib 100 mg/kg (orally) coadministered with acetaminophen intraperitoneally (700 mg/kg)"><entity charOffset="50-58" id="DDI-PubMed.20523867.s6.e0" text="imatinib" /><entity charOffset="69-77" id="DDI-PubMed.20523867.s6.e1" text="imatinib" /><entity charOffset="117-130" id="DDI-PubMed.20523867.s6.e2" text="acetaminophen" /><pair ddi="false" e1="DDI-PubMed.20523867.s6.e0" e2="DDI-PubMed.20523867.s6.e0" /><pair ddi="false" e1="DDI-PubMed.20523867.s6.e0" e2="DDI-PubMed.20523867.s6.e1" /><pair ddi="false" e1="DDI-PubMed.20523867.s6.e0" e2="DDI-PubMed.20523867.s6.e2" /><pair ddi="false" e1="DDI-PubMed.20523867.s6.e1" e2="DDI-PubMed.20523867.s6.e1" /><pair ddi="false" e1="DDI-PubMed.20523867.s6.e1" e2="DDI-PubMed.20523867.s6.e2" /></sentence><sentence text=" Mice were euthanized at predetermined time points, blood samples collected, and imatinib plasma concentration measured by HPLC"><entity charOffset="81-89" id="DDI-PubMed.20523867.s7.e0" text="imatinib" /></sentence><sentence text="" /><sentence text="Imatinib AUC(0-12) was 27"><entity charOffset="0-18" id="DDI-PubMed.20523867.s9.e0" text="Imatinib AUC(0-12)" /></sentence><sentence text="04 +/- 0" /><sentence text="38 mg" /><sentence text="h/ml, C(max) was 7" /><sentence text="21 +/- 0" /><sentence text="99 mg/ml and elimination half-life was 2" /><sentence text="3 hours" /><sentence text=" Acetaminophen affected the imatinib disposition profile: AUC(0-12) and C(max) decreased 56% and 59%, respectively and a longer half-life was observed (5"><entity charOffset="1-14" id="DDI-PubMed.20523867.s16.e0" text="Acetaminophen" /><entity charOffset="28-36" id="DDI-PubMed.20523867.s16.e1" text="imatinib" /><pair ddi="false" e1="DDI-PubMed.20523867.s16.e0" e2="DDI-PubMed.20523867.s16.e0" /><pair ddi="false" e1="DDI-PubMed.20523867.s16.e0" e2="DDI-PubMed.20523867.s16.e1" /></sentence><sentence text="6 hours)" /><sentence text="" /><sentence text="The study shows a pharmacokinetic interaction between acetaminophen and imatinib which may render further human studies necessary if both drugs are administered concurrently to cancer patients"><entity charOffset="54-67" id="DDI-PubMed.20523867.s19.e0" text="acetaminophen" /><entity charOffset="72-80" id="DDI-PubMed.20523867.s19.e1" text="imatinib" /><pair ddi="false" e1="DDI-PubMed.20523867.s19.e0" e2="DDI-PubMed.20523867.s19.e0" /><pair ddi="false" e1="DDI-PubMed.20523867.s19.e0" e2="DDI-PubMed.20523867.s19.e1" /></sentence><sentence text="" /></document>